Inventor · disambiguated record
Jordi Mata-Fink
Also filed as: MATA-FINK JORDI
27 granted patents·40 pending applications·399 citations·filing 2014–2024
97Inventor score
Files withRUBIUS THERAPEUTICS INC42FLAGSHIP PIONEERING INNOVATIONS V INC14EDITAS MEDICINE INC8FLAGSHIP PIONEERING INNOVATIONS VI LLC1GATE BIOSCIENCE INC1
Top patents by PatentIndex Score
67 records- 0198US10190137B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2017·Granted Jan 29, 2019·37 cites·26 claims
- 0298US9834791B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2014·Granted Dec 5, 2017·97 cites·30 claims
- 0398US9644180B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·98 cites·21 claims
- 0497US11390887B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2020·Granted Jul 19, 2022·6 cites·8 claims
- 0597US10640788B2CRISPR-related methods and compositions with governing gRNAsEDITAS MEDICINE INC·Filed 2019·Granted May 5, 2020·18 cites·25 claims
- 0697US10344263B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jul 9, 2019·14 cites·25 claims
- 0797US10329531B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·18 cites·29 claims
- 0897US10253296B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·16 cites·24 claims
- 0996US10301594B1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·11 cites·29 claims
- 1095US10683352B1Methods for treating cancer using GRM8 inhibitorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Granted Jun 16, 2020·20 cites·1 claims
- 1195US10301593B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·8 cites·27 claims
- 1294US11034751B1Methods and compositions for treating cancer using serotonin receptor inhibitorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Granted Jun 15, 2021·17 cites·15 claims
- 1394US10456421B2Compositions and methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2017·Granted Oct 29, 2019·10 cites·20 claims
- 1493US10869898B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2015·Granted Dec 22, 2020·6 cites·25 claims
- 1592US10557119B2Erythroid cells comprising phenylalanine ammonia lyaseRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 11, 2020·4 cites·27 claims
- 1692US10517897B1Methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2019·Granted Dec 31, 2019·4 cites·28 claims
- 1790US10568910B2Compositions and methods related to engineered erythroid cells comprising IL-15RUBIUS THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·3 cites·18 claims
- 1888US10457740B1Methods and compositions for treating cancer using P2RX2 inhibitorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2018·Granted Oct 29, 2019·6 cites·1 claims
- 1986US11208475B1Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activatorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Granted Dec 28, 2021·3 cites·10 claims
- 2083US2023293588A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer IndicationsRUBIUS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2180US11059886B1Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activatorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Granted Jul 13, 2021·1 cites·20 claims
- 2280US2022389460A1CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
- 2380US2024067992A1Human hematopoietic stem cell having a modified bcl11a gene and methods of making the cellEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 2478US2022072048A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune IndicationsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2577US11013717B1Methods and compositions for treating cancer using SERCA pump inhibitorsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2019·Granted May 25, 2021·1 cites·10 claims
- 2675US10716811B2Compositions and methods related to multimodal therapeutic cancer indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jul 21, 2020·0 cites·20 claims
- 2775US2020002674A1Erythroid cells comprising phenylalanine hydroxylaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2875US2019309262A1Erythroid cells comprising serine dehydrataseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2975US2019309261A1Erythroid cells comprising lysine oxidaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3075US2019316091A1Erythroid cells comprising arginaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3175US2019376034A1Platelets comprising exogenous polypeptides and uses thereofRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3275US2019316090A1Erythroid cells comprising arginine deiminaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3374US2019388473A1Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3472US11020435B2Functionalized erythroid cellsRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jun 1, 2021·1 cites·44 claims
- 3572US2018216067A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3672US2018265847A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3771US2015182588A1Synthetic membrane-receiver complexesVL26 INC·Filed 2014·Application pending·0 cites
- 3871US2020129556A1Compositions and methods related to engineered erythroid cells comprising il-15RUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3971US2018187153A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4071US2018187154A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4170US2018187155A1Compositions and methods related to multimodal therapeutic cell systems for autoimmune indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4269US2021177823A1Neuromodulating compositions and related therapeutic methods for the treatment of cancerFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2020·Application pending·0 cites
- 4369US2021154272A1Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune responseFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2020·Application pending·0 cites
- 4468US2022073875A1Amplifiable RNAs for Therapeutic Cell SystemsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4567US2021040506A1Crispr-related methods and compositionsEDITAS MEDICINE INC·Filed 2020·Application pending·0 cites
- 4666US11576934B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 14, 2023·0 cites·20 claims
- 4766US2016257932A1Genetically engineered enucleated erythroid cells comprising a phenylalanine ammonia lyase receiver polypeptideRUBIUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4864US2021180015A1Membrane-Receiver Complex TherapeuticsRUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4963US11554141B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jan 17, 2023·0 cites·18 claims
- 5063US2016237455A1Crispr-related methods and compositionsEDITAS MEDICINE INC·Filed 2014·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jordi Mata-Fink files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →